Prescription medicine
Ipratropium Brand names: Atrovent
Ipratropium (Atrovent) is a prescription medicine with an FDA approval on record since 1986. FDA's NDC Directory lists it from 23 generic labelers, and pharmacies paid $0.111 per mL (Ipratropium br 0.02% solution) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the ipratropium FDA label on DailyMed (effective January 8, 2026, Lupin Pharmaceuticals, Inc.); the NDA 19085 record on Drugs@FDA; every ipratropium label on DailyMed.
Highlights of the record
FDA label of January 8, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageIpratropium bromide nasal solution, 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older.
Forms and strengths
- 0.5 mg/2.5ml
Solution; spray (metered); spray; aerosol (metered); aerosol.
On the market
- Earliest approval on file
- December 29, 1986 Atrovent, Boehringer Ingelheim; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 28 first January 10, 1997; 16 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 24 of which 23 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- January 17, 2030 Atrovent Hfa aerosol; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.111 per mL Ipratropium br 0.02% solution
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2022 0 Class I among all firms' recalls; latest April 13, 2022
- FAERS reports
- 35,481 through July 30, 2026
What is ipratropium used for?
From the label: indications and usageIpratropium bromide nasal solution, 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium bromide 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis.
Conditions named in the indications of ipratropium's FDA labels, with every medicine labeled for each:
From other ipratropium labelsCOPD: … indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Allergies and Cough and cold: INDICATIONS AND USAGE Ipratropium bromide nasal solution 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children age 5 years and older.
FDA pharmacologic class: Anticholinergic.
Source: FDA drug label (IPRATROPIUM BROMIDE), Lupin Pharmaceuticals, Inc., effective January 8, 2026 (SPL set 13a45df5-a8e3-41d6-91f4-773255b5a04b), via openFDA; the full label on DailyMed
Is there a generic for ipratropium (Atrovent)?
The FDA approved the first generic ipratropium on January 10, 1997. 28 generic applications are approved; 16 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists ipratropium from 23 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 1 patent for Atrovent Hfa aerosol, the last expiring on January 17, 2030. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1986 earliest approval on file
- 1997 first generic approved
- 2030 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for ipratropium (Atrovent)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.111 per mL (Ipratropium br 0.02% solution), up 11% from $0.0997 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ipratropium br 0.02% solution (generic)
- Atrovent 17 mcg hfa inhaler (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ipratropium 0.03% spray | Generic | $0.368 per mL | n/a | -36% |
| Ipratropium 0.06% spray | Generic | $0.778 per mL | n/a | -27% |
| Ipratropium br 0.02% solution | Generic | $0.111 per mL | n/a | +11% |
| Ipratropium br 17 mcg hfa inhaler | Generic | $22.11 per gram | n/a | n/a |
| Atrovent 17 mcg hfa inhaler | Brand | $22.76 per gram | n/a | -0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has ipratropium been recalled?
The FDA's Enforcement Report lists 1 recall naming ipratropium since 2022: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| April 13, 2022 | Class II | Mckesson Medical-Surgical Inc. Corporate Office | cGMP deviations: Temperature abuse |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the ipratropium label say about other medicines?
The ipratropium label names 2 other medicines in its interaction, contraindication or warning sections. The labels of 5 other medicines name ipratropium. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Albuterol | drug interactions | With the exception of albuterol, there are no formal studies fully evaluating the interaction effects of ATROVENT HFA and these drugs with respect to safety and effectiveness. |
| Atropine | contraindications | CONTRAINDICATIONS Ipratropium bromide nasal solution, 0.03% is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients. |
Other labels that name ipratropium
Source: FDA drug label (IPRATROPIUM BROMIDE), Lupin Pharmaceuticals, Inc., effective January 8, 2026 (SPL set 13a45df5-a8e3-41d6-91f4-773255b5a04b), via openFDA; the full label on DailyMed
What do FAERS reports show for ipratropium?
The FDA Adverse Event Reporting System holds 35,481 reports that list ipratropium among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 4,693 are coded as a death and 15,676 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
How does ipratropium compare with medicines for the same use?
3 side-by-side pages set ipratropium beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Other anticholinergics
- the pharmacologic class, with prices and generics
- Ipratropium side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other